anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-15 and is reviewed periodically as new material appears.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Sodium dodecyl sulfate (SDS), a common detergent, may be found in protein extracts because it is used to lyse cells by disrupting the membrane lipid bilayer and to denature proteins for SDS-PAGE. While other detergents interfere with the assay at high concentration, the interference caused by SDS is of two different modes, and each occurs at a different concentration. When SDS concentrations are below critical micelle concentration (known as CMC, 0.00333%W/V to 0.0667%) in a Coomassie dye solution, the detergent tends to bind strongly with the protein, inhibiting the protein binding sites for the dye reagent. This can cause underestimations of protein concentration in solution. When SDS concentrations are above CMC, the detergent associates strongly with the green form of the Coomassie dye, causing the equilibrium to shift, thereby producing more of the blue form. This causes an increase in the absorbance at 595 nm independent of protein presence. Other interference may come from the buffer used when preparing the protein sample. A high concentration of buffer will cause an overestimated protein concentration due to depletion of free protons from the solution by conjugate base from the buffer. This will not be a problem if a low concentration of protein (subsequently the buffer) is used. In order to measure the absorbance of a colorless compound a Bradford assay must be performed.
== History == Cranio-lenticulo-sutural dysplasia was first discovered by Simeon Boyadjiev Boyd, chief of the Section of Genetics at UC Davis Children's Hospital, in 2003. CLSD was found a consanguineous (sharing a common ancestor) Saudi Arabian family of Bedouin descent. The children who were affected inherited the defective gene from both of their parents (Boyadjiev, 1193). A Caucasian male was also found to have symptoms of the disease, but possessed only one defective chromosome. Measurements of the endoplasmic reticulums of his mother and father showed that the mother had a normal phenotype, the father had a slightly distended endoplasmic reticulum, and the affected son had an endoplasmic reticulum distended to a much greater extent. Because of the normal measurements obtained from the mother, it was concluded that the father was responsible for the son's symptoms and was hypothesized that there was another mutation on chromosome 14 that caused the disease to manifest itself without a secondary disease carrying chromosome he would have inherited from his mother. It is associated with a mutation changing the translation of phenylalanine to leucine in SEC23A.
The most difficult steps in synthesising berkelium were its separation from the final products and the production of sufficient quantities of americium for the target material. First, americium (241Am) nitrate solution was coated on a platinum foil, the solution was evaporated and the residue converted by annealing to americium dioxide (AmO2). This target was irradiated with 35 MeV alpha particles for 6 hours in the 60-inch cyclotron at the Lawrence Radiation Laboratory, University of California, Berkeley. The (α,2n) reaction induced by the irradiation yielded the 243Bk isotope and two free neutrons:
Sources: en.wikipedia.org
The League adopted the argument that no one segment of any mandate's population was entitled to favourable treatment over another, and the terms under which the mandate had been granted made no provision for special obligation towards whites. It pointed out that there was little evidence of progress being made towards political self-determination. Just prior to World War II, South Africa and the League remained at an impasse over this dispute.
=== Buoyancy control === Surface-supplied divers may be required to work in mid-water or on the bottom. They must be able to stay down without effort, and this usually requires weighting. When working in mid-water the diver may wish to be neutrally buoyant or negative, and when working on the bottom, will usually want to be several kilograms negative. The only time the diver may want to be positively buoyant is when on the surface or during a limited range of emergencies where uncontrolled ascent is less life-threatening than remaining under water. Surface-supplied divers generally have a secure supply of breathing gas, and there are very few occasions where weights should be jettisoned, so in most cases the surface-supplied diver weighting arrangement does not provide for quick release. On those occasions when surface supplied divers need variable buoyancy, it may be provided by inflation of the dry suit, if used, or by a buoyancy control device similar in principle to those used by scuba divers, or both.
=== Biological strategies === It has become possible to accelerate natural aerobic, anaerobic, and sequential aerobic and/or anaerobic biological processes to minimize the presence of NAPLs in the subsurface environment. Most bioremediation strategies rely on the presence of specific populations of bacteria/microorganisms and the addition of organic carbon to stimulate biodegradation. This organic carbon can be supplied via injection of soluble organic carbon sources such as lactate, alcohols, cheese whey, etc. and placement of slow-release electron donors such as vegetable oil and soybean oil emulsions. Sufficient dissolved oxygen must be present for aerobic biodegradation, which can be supplied through strategies including air sparging and SVE. That said, the ability to supply sufficient oxygen is a limiting factor affecting the success of this type of remediation strategy. Also, many cases require the presence of inducers such as methane, propane, ammonia, or toluene, which are contaminants in and of themselves that are inherently harmful to the subsurface environment. Yet another challenge is maintaining a sufficient population of bacteria/microorganisms in the face of competition from native bacteria and other external pressures. There is also regulatory pushback to the use of genetically modified bacteria. Furthermore, NAPLs may not be readily bioavailable, limiting the effectiveness of biodegradation strategies. In this sense, biodegradation may not be appropriate as a single solution, but it can certainly be used in conjunction with other strategies.
1 L-ornithine2 carbamoyl phosphate3 L-citrulline4 argininosuccinate5 fumarate6 L-arginine7 urea L-Asp L-aspartateCPS-1 carbamoyl phosphate synthetase IOTC Ornithine transcarbamoylaseASS argininosuccinate synthetaseASL argininosuccinate lyaseARG1 arginase 1
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.